title: Intravenous naloxone plus transdermal buprenorphine in cancer pain associated with intractable cholestatic pruritus.
authors.forename: Franco
authors.initials: F
authors.lastname: Marinangeli
authors.forename: Cristiana
authors.initials: C
authors.lastname: Guetti
authors.forename: Chiara
authors.initials: C
authors.lastname: Angeletti
authors.forename: Cristina
authors.initials: C
authors.lastname: Bonetti
authors.forename: Antonella
authors.initials: A
authors.lastname: Paladini
authors.forename: Alba
authors.initials: A
authors.lastname: Piroli
authors.forename: Giustino
authors.initials: G
authors.lastname: Varrassi
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage; D002047:Buprenorphine / Q000008:administration & dosage*; D002779:Cholestasis / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D009270:Naloxone / Q000008:administration & dosage*; D009292:Narcotic Antagonists / Q000008:administration & dosage; D009369:Neoplasms / Q000150:complications* / Q000451:nursing; D010146:Pain / Q000209:etiology* / Q000517:prevention & control*; D010147:Pain Measurement / Q000187:drug effects; D010166:Palliative Care / Q000379:methods; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D004338:Drug Combinations; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine